Hemostemix Announces Appointment of Director and Postponement of Annual and Special Meeting

Author's Avatar
Dec 03, 2019
Article's Main Image

CALGARY, Alberta, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTC: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments, announces the appointment of Mr. Bryson Goodwin as a director of the Company (“the “Board”) effective December 2, 2019, subject to customary TSX Venture Exchange (“TSXV”) approval.